FDA Clearance Tracker · P250039
LIAISON Biotrin Parvovirus B19 IgM Plus, LIAISON Biotrin Control Parvovirus B19 IgM Plus
Last checked: Nov 19, 2026Latest source record: May 7, 2026 (this decision)Source: openFDAMethods & limitations
Decided
May 7, 2026
Approved
Time to decision
220 days
Received Sep 29, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P250039
- Device name
- LIAISON Biotrin Parvovirus B19 IgM Plus, LIAISON Biotrin Control Parvovirus B19 IgM Plus
- Applicant
- DiaSorin, Inc.
- Applicant location
- Stillwater, MN
- Received
- Sep 29, 2025
- Decided
- May 7, 2026
- Decision
- Approved
- Supplements
- 1 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for LIAISON Biotrin Parvovirus B19 IgM Plus and LIAISON Biotrin Control Parvovirus B19 IgM Plus. The LIAISON Biotrin Parvovirus B19 IgM Plus, a chemiluminescent immunoassay (CLIA), is intended for the qualitative detection of IgM antibodies to human parvovirus B19 in human serum, lithium heparin, K2-EDTA and sodium citrated plasma. This test, in conjunction with the LIAISON Biotrin Parvovirus B19 IgG Plus (chemiluminescent immunoassay), may be used for testing women of childbearing age to determine their serological status where there is a suspicion of exposure to human parvovirus B19. The results of these assays may be used to make a serological determination of past, recent, or current infection with parvovirus B19. The test may also be used for all patients as an aid in the diagnosis of fifth disease (erythema infectiosum). The test must be performed on the LIAISON XL Analyzer.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code MYM. The earliest in FDA's data is P970055, decided Aug 6, 1999.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for DiaSorin, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260770 · Decided Jun 4, 2026 · 87 days after receipt
Device type: Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen) (LOM) · Laboratory Medicine & Pathology
- LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261)New device typeBreakthroughDe Novo
DEN250032 · Decided Dec 23, 2025 · 146 days after receipt
Device type: Device To Detect Antibodies To Hepatitis D Virus (SGW) · Laboratory Medicine & Pathology
P220034 · Decided Mar 29, 2024 · 458 days after receipt
Device type: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGG (MYL) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.